Zhejiang Garden Biopharmaceutical Co.,Ltd.

Zhejiang Garden Biopharmaceutical Co.,Ltd.

SSZSE:300401
11.47
CNY
+0.07
(+0.61%)
0.40EPS
35.40P/E
8.40BMarket Cap
Mar 31Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.54
0.39
0.35
0.72
2.32
1.37
1.5
1.3
2.06
2.59
1.99
2.29
2.27
2.32
Basic EPS, GAAP
0.11
0.09
0.03
0.1
0.72
0.64
0.72
0.52
0.89
0.7
0.35
0.57
0.56
0.44
Free Cash Flow per Basic Share
0.19
-0.28
-0.21
-0.02
0.42
0.07
-0.17
-0.33
-0.37
-0.01
-0.15
-0.03
0.21
- -
Dividend per Share
- -
- -
0.02
0.01
0.06
0.06
0.14
0.02
0.12
0.22
0.19
0.12
0.17
0.23
Book Value per Share
1.75
1.56
1.57
1.66
2.67
3.26
3.64
5.24
4.14
4.67
5.25
5.92
6.42
6.63
Tangible Book Value per Share
1.68
1.51
1.44
1.52
2.48
2.91
3.28
4.9
3.81
4.32
4.89
5.54
5.92
6.11
Basic Weighted Avg Shares
340
405
431
456
181
480
477
506
544
548
550
542
544
548
Sales/Revenue/Turnover
184
159
151
329
420
660
718
659
1,117
1,418
1,095
1,243
1,237
1,271
Operating Margin (%)
17.39
23.16
1.75
14.77
37.79
52.1
52.96
43.02
44
29.74
19.88
27.89
30.95
25.25
Depreciation Expense
16
14
14
32
34
37
39
46
45
61
133
156
178
- -
Net Income, GAAP
36
37
12
44
130
307
344
263
484
384
192
309
305
239
Effective Tax Rate (%)
8.77
14.76
- -
13.68
13.91
13.78
13.8
9.42
12.8
13.28
8.86
13.8
13.52
12.89
Profit Margin (%)
19.56
23.47
7.98
13.3
31.06
46.56
47.84
39.92
43.31
27.07
17.57
24.87
24.64
18.76
Working Capital
369
378
228
260
760
886
680
1,217
213
78
1,198
1,195
1,458
1,260
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
923
1,054
1,258
1,084
Total Equity
616
709
712
753
1,281
1,562
1,743
2,879
2,283
2,572
2,893
3,218
3,489
3,611
Return on Invested Capital (%)
5.56
5.28
- -
5.05
12.15
21.06
19.15
10.05
17.42
12.67
4.81
6.33
5.85
4.52
Return on Capital (%)
6.35
5.67
- -
5.91
12.44
21.4
19.62
10.69
15.92
13.66
5.85
7.08
6.49
5.04
Return on Common Equity (%)
6.5
5.71
1.7
5.98
12.82
21.63
20.8
11.37
18.72
15.81
7.04
10.12
9.09
6.86

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
844
693
773
LT Borrowings
1,148
1,145
1,083
LT Finance Leases
- -
- -
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
544
545
545
Market Capitalization
7,590
11,926
8,396

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,588
2,468
2,448
Cash, Cash Equivalents & STI
1,639
1,368
1,383
Accounts Receivable, Net
137
240
178
Inventories
758
743
798
Total Current Liabilities
1,242
1,134
1,188
Payables & Accruals
- -
- -
- -
ST Debt
844
693
773
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.87%
4.82%
8.41%
Free Cash Flow
37.12%
352.31%
-907.16%
Net Income, GAAP
65.72%
14.52%
-1.41%
Sales/Revenue/Turnover
28.97%
17.32%
-0.47%
Total Cash Common Dividend
98.17%
125.38%
36.74%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
330
270
337
306
1,243
2025
326
309
- -
302
1,237
2026
277
415
278
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.09
0.18
0.13
0.57
2025
0.18
0.12
- -
0.13
0.56
2026
0.09
0.15
0.07
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.08
0.01
0.01
0.12
2025
0.02
0.12
- -
0.01
0.17
2026
0.03
0.12
0.07
- -
- -

Company Description

CEO
Huan Zheng Ma
Full Time Employees
1,163
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 2, Huayuan Kangping Road Jinhua ZJ China 322121
IPO Date
Oct 8, 2014
Business
Zhejiang Garden Biopharmaceutical Co., Ltd. (300401.SZ) manufactures and supplies vitamin D3, cholesterol, and related derivatives for applications in food additives, animal nutrition, human health products, and pharmaceuticals. Founded in 2000 and headquartered in Dongyang, Zhejiang Province, China, the company operates primarily in China with exports to Europe, North America, South America, and East Asia; it listed on the Shenzhen Stock Exchange's Growth Enterprise Market in 2014 and changed its name from Zhejiang Garden Bio-chemical High-tech Co., Ltd. in April 2023 to reflect its expanded biopharmaceutical focus. Core products include lanolin cholesterol; feed-grade vitamin D3 particles, oil, and resin; 25-hydroxyvitamin D3 in powder and progen forms; refined and anhydrous lanolin; lanolin alcohol; lanolin fatty acid; isopropyl lanolate; vitamin A and AD3 particles; cholecalciferol; compound nutrient fortifiers such as SDS, CO, and MO; wood oil and wool wax derivatives; low chroma pure fat; high acid fat; wood acid and alcohol biofuels; and Vitamin D3-based rodenticides; the company also produces chemical drugs and Chinese patent medicines, including Alendronate Sodium Tablets through its wholly-owned subsidiary Zhejiang Gelon Biochemical Co., Ltd. Recent developments encompass the selection of its subsidiary's Alendronate Sodium Tablets for China's 11th round of national centralized drug procurement in November 2025, enhancing pharmaceutical market share; commencement of a 6,000-ton annual vitamin A powder production project; strong 2025 financial performance with third-quarter revenue growth and improved net profit amid cost controls and rising lanolin output; sustained 30-40% domestic market share in vitamin D3; and strategic "one vertical, one horizontal" expansion, deepening the vitamin D3 chain while pursuing mergers in global vitamin markets; in 2018-2021, it relocated to the 771-acre Jinxi Science and Technology Park for advanced digital production compliant with environmental standards.